Landmark studies such as LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have shown significant reductions in major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors
for the incretin comparison, see Semaglutide vs Tirzepatide
Semaglutide also has FDA approval for heart and kidney protection, while tirzepatide does not
Embrace a naturally sculpted silhouette and bid farewell to persistent fat with Lemon Bottle, your ultimate solution for a refined figure
The safety profile of berobenatide in VESPER-3 was consistent with the GLP-1 RA class, and no new safety signals were identified, supporting the switch from weekly to monthly dosing